GlassScriptPhysician profile
Jared D Wilkinson
NPI 1699111542
$2,689.49
in general payments reported to CMS, 2019-2025
21 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $196 · 2024: $993 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,610.50 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $774.85 | 2023-2025 | Remodulin, Orenitram, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.25 | 2023-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $376.42 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Abbvie INC. | $175.23 | 2023-2025 | Avycaz |
| Bayer Healthcare Pharmaceuticals INC. | $149.36 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.84 | 2024-2025 | Livtencity |
| Melinta Therapeutics, LLC | $126.23 | 2024-2025 | Rezzayo, Vabomere |
| Ani Pharmaceuticals, INC. | $86.26 | 2024 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $67.76 | 2024-2025 | Nuzyra |
| Astellas Pharma US INC | $65.66 | 2025 | Cresemba |
| Merck Sharp & Dohme LLC | $51.62 | 2024-2025 | Winrevair |
| Mylan Specialty L.P. | $46.40 | 2023 | Tobi Podhaler |
| Vertex Pharmaceuticals Incorporated | $45.24 | 2023-2025 | Trikafta |
| Grifols Shared Services North America, INC. | $42.03 | 2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $34.63 | 2024-2025 | Zemaira |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $31.35 | 2025 | Pemgarda |
| Insmed, INC. | $24.54 | 2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $21.55 | 2024 | Farxiga |
| Verona Pharma, INC. | $20.87 | 2025 | Ohtuvayre |
| Baxter Healthcare | $19.24 | 2025 | Hillrom - Monarch Airway Clearance System |
| Sandoz INC. | $15.16 | 2024 | Treprostinil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.